Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

This publication has 23 references indexed in Scilit:

• Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies
  Journal of Clinical Oncology, 2012
• Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
  European Journal of Cancer, 2012
• Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib
  European Urology, 2011
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
  The Lancet, 2011
• Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
  Journal of Clinical Oncology, 2010
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
  Journal of Clinical Oncology, 2010
• Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
  British Journal of Cancer, 2009
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
  BMC Cancer, 2009
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
  The Lancet, 2008
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2007